Press Release

Carl Zeiss Meditec AG achieves increase in profit in first quarter 2020/21

19 January 2021

Jena, Germany | Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of €368.9m in the first quarter of fiscal year 2020/21 (previous year: €369.7m). This corresponds to a revenue development of -0.2% vs. the past year (after adjustment for currency effects1: +2.6%).

Earnings before interest and taxes (EBIT)2 amounted to €73.4m in the first quarter of fiscal year 2020/21 (previous year: €56.8m). EBIT margin (EBIT / revenue) was 19.9% (prior year 15.4%). EBIT development benefitted in part from lower sales and marketing expenses compared to the previous year’s period. In addition, EBIT includes a one-time gain from the sale of a property in the amount of around EUR 2.4 million in the current period.

Earnings per share (EPS)3 amounted to €0.52 (past year: €0.43).

Full results for the first half 2020/21 will be published on February 8, 2021.

During the further course of fiscal year 2020/21, the company expects the recovery in revenue and EBIT to continue compared to the previous year, which had seen a marked impact from the COVID-19 pandemic.

Press & Investor Relations Contact Sebastian Frericks

Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

 


Share this article

  • 1

    Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.

  • 2

    Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2019/20, p. 80 for reconciliation).

  • 3

    Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2019/20, p. 80 for reconciliation).